<DOC>
	<DOC>NCT00581165</DOC>
	<brief_summary>Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the development of adverse reactions.</brief_summary>
	<brief_title>Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1. Informed consent signed by patients prior to study entry 2. 18 years of age or older at screening visit 3. Patients with moderate to severe psoriasis 4. Patients who have failed conventional systemic treatment 5. Patients who have a contraindication to conventional systemic therapy 6. Patients who are intolerant to conventional systemic therapy 7. A negative serum pregnancy test at screening in women of childbearing potential 8. Able to selfinject study drug or have a designee who can do so 9. In the opinion of the investigator, the patient will be able to comply with the requirements of the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>